Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 5/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844025 | 1.00 | BLM (0.59) | BLMSMN1; SMN2HIF1AESR1ESR2 | |
| SCHEMBL27747412 | 0.92 | BLM (0.56) | BLMSMN1; SMN2HIF1AESR1ESR2 | |
| SCHEMBL5844669 | 0.88 | SMN1; SMN2 (0.49) | BLMSMN1; SMN2HIF1AKDM4EALDH1A1 | |
| SCHEMBL27616082 | 0.88 | SMN1; SMN2 (0.49) | BLMSMN1; SMN2HIF1AKDM4EALDH1A1 | |
| SCHEMBL6464407 | 0.88 | SMN1; SMN2 (0.66) | BLMSMN1; SMN2HIF1ACTSSCTSK | |
| SCHEMBL4937591 | 0.88 | SMN1; SMN2 (0.66) | BLMSMN1; SMN2HIF1ACTSSCTSK | |
| SCHEMBL5843911 | 0.87 | CYP3A4 (0.49) | BLMSMN1; SMN2HIF1ACTSKKDM4E | |
| SCHEMBL5031241 | 0.87 | SMN1; SMN2 (0.47) | BLMSMN1; SMN2HIF1ACTSSCTSK | |
| SCHEMBL16553913 | 0.87 | SMN1; SMN2 (0.47) | BLMSMN1; SMN2HIF1ACTSSCTSK | |
| SCHEMBL5844647 | 0.87 | SMN1; SMN2 (0.47) | BLMSMN1; SMN2HIF1ACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101959405-B | Oxadiazaanthracene compounds for the treatment of diabetes | TRANSTECH PHARMA INC | 2014-07-02 | — | — | CN | disclosed |
| CN-102056922-B | Macrocyclic urea and sulfonamide derivatives as TAFIA inhibitors | SANOFI AVENTIS | 2013-11-20 | — | — | CN | disclosed |
| US-8362236-B2 | Macrocyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-2119718-B1 | MACROCYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-04-11 | — | — | EP | disclosed |
| CN-102056922-A | Macrocyclic urea and sulfonamide derivatives as TAFIA inhibitors | SANOFI AVENTIS | 2011-05-11 | — | — | CN | disclosed |
| CN-101969952-A | Compositions comprising tryptophan hydroxylase inhibitors | LEXICON PHARMACEUTICALS INC | 2011-02-09 | — | — | CN | disclosed |
| CN-101815534-A | methods and compositions for treating pulmonary hypertension and related diseases and disorders | LEXICON PHARMACEUTICALS INC | 2010-08-25 | — | — | CN | disclosed |
| CN-101801385-A | Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein | LEXICON PHARMACEUTICALS INC | 2010-08-11 | — | — | CN | disclosed |
| CN-101784269-A | methods of treating serotonin-mediated diseases and disorders | LEXICON PHARMACEUTICALS INC | 2010-07-21 | — | — | CN | disclosed |
| CN-101675059-A | Macrocyclic compounds | CHUGAI PHARMACEUTICAL CO LTD | 2010-03-17 | — | — | CN | disclosed |
| US-20100056510-A1 | Macrocyclic Compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119718-A1 | MACROCYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2009-11-18 | — | — | EP | disclosed |
| CN-1703221-A | 2-alkyl- (2-amino-3-aryl-propionyl) -piperazine derivatives and related compounds as melanocortin receptor ligands for the treatment of obesity | PROCTER & GAMBLE (US) | 2005-11-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056510-A1 | Macrocyclic Compound | HSP90AB1, HSP90B1, HSP90AA1 | BLM 2353/4885SMN1; SMN2 4555/4885HIF1A 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.